Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis

Phase 3 Study Results

Panés, Julian MD, PhD
Loftus, Edward V Jr MD
Higgins, Peter D R MD, PhD, MS
Lindsay, James O PhD, FRCP
Zhou, Wen MD, PhD
Yao,, Xuan
Ilo, Dapo MD
Phillips, Charles MD
Tran, Jacinda PharmD
Sanchez Gonzalez, Yuri PhD
Vermeire, Séverine MD, PhD

Inflammatory Bowel Disease Unit, Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA
Department of Medicine, University of Michigan, Ann Arbor, MI, USA
Department of Gastroenterology, Royal London Hospital, Barts Health NHS Trust, London, United Kingdom
AbbVie Inc, North Chicago, IL, USA
AbbVie Inc, North Chicago, IL, USA
AbbVie Inc, North Chicago, IL, USA
AbbVie Inc, North Chicago, IL, USA
AbbVie and the Comparative Health Outcomes, Policy, and Economics Institute, University of Washington, Seattle, WA, USA
AbbVie Inc, North Chicago, IL, USA
Department of Gastroenterology and Hepatology, University Hospital Leuven, Leuven, Belgium

Address correspondence to: Julian Panés, MD, PhD, Inflammatory Bowel Disease Unit, Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, C/Rosselló 149-153, 08036 Barcelona, Spain ([email protected]).

Received August 08, 2022

Revised January 16, 2023

Online date: January 16, 2023

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [email protected]

Inflammatory Bowel Diseases 29(9):p 1421-1430, September 01, 2023. | DOI: 10.1093/ibd/izac260

Lay Summary

Patients with moderate-to-severe ulcerative colitis who received upadacitinib induction treatment demonstrated clinically meaningful improvements across multiple health-related quality of life assessments, as early as induction week 2, that persisted with maintenance treatment to 52 weeks, compared with placebo.